Progress in radiotherapy and expression of PD-L1 in esophageal cancer

Xiangyong Liu1 and Ying Sun2*

1Department of Radiotherapy, Qilu Hospital of Shandong University, Qingdao, China
2Department of Medical Oncology, Qilu Hospital of Shandong University, Qingdao, China

Abstract
Esophageal cancer is a malignant tumor with high morbidity and mortality in China, and the overall prognosis is poor. Finding new treatment methods is a hot topic at home and abroad. This article summarizes the relationship between PD-L1 expression and clinical pathology and prognosis of esophageal cancer, the effect of radiotherapy on the expression of PD-L1, and finally discusses the effect of radiotherapy on PD-1/PD-L1 treatment. It is suggested that the up-regulation of PD-L1 in the tumor microenvironment not only shows immunosuppression, but also is related to endogenous anti-tumor immune activity. The prognosis of patients is affected by both immunosuppression and activation. Radiotherapy can up-regulate the expression of PD-L1 in esophageal squamous cell carcinoma, and radiotherapy combined with anti-PD-1/PD-L1 treatment has synergistic effect. Then the mechanism behind it is complicated, and there are many signal transduction pathways involved, which needs further study.

Introduction
According to the latest data released by the National Cancer Center, the number of new cases of esophageal cancer in China in 2014 was 258,000, ranking 6th in malignant tumors, and the number of deaths was 193,000, ranking fourth in all malignant tumors [1]. More than 90% of esophageal cancers are squamous cell carcinomas. Despite the use of surgery, radiotherapy, chemotherapy and other comprehensive treatments, the prognosis of advanced esophageal cancer is still very poor, the 5-year survival rate is only 15% to 25% [2]. Therefore, researching new treatments to improve the prognosis of esophageal cancer is an urgent need at home and abroad. The emergence of immunological checkpoint inhibitors has brought milestones to immunotherapy. In recent years, immunological checkpoint inhibitors have been used to treat diseases such as non-small cell lung cancer, malignant melanoma, Hodgkin’s lymphoma, and have shown surprising effects. However, the effectiveness of immunological checkpoint inhibitors alone is only about 20%, and immunization combined with other anti-tumor treatments is currently a hot topic. PD-L1 expression was used as a predictor of immunological checkpoint inhibitors, while high expression of PD-L1 was thought to be associated with radiation resistance [3]. The relationship between radiotherapy of esophageal cancer and PD-L1 expression is reviewed.

Overview of PD-1 and PD-L1
In 1992, Ishida, et al. [4] first discovered PD-1 (CD279), a member of the CD28 family member type I transmembrane glycoprotein, including the extracellular amino acid head, transmembrane domain, and cytoplasmic region amino acid tail, which contains immunity. The receptor tyrosine-based swith motif (ITSM) and the immunoreceptor tyrosine-based inhibitory motif (ITIM) [5]. Mainly expressed in peripheral CD4+ T cells, CD8+ T cells, regulatory T cells, B cells, dendritic cells (DCs), activated monocytes, natural killer cells (NK cells) and natural killer T cells. PD-1 is produced when T cells are stimulated by inflammation, and binds to their ligands in peripheral tissues mainly composed of tumors and infections [6]. The ligands of PD-1 are PD-L1 and PD-L2, but only PD-L1 is expressed in peripheral tissues, so PD-1 mainly acts on PD-L1 in the periphery. PD-L1 (CD274) belongs to the B7 superfamily and is also a type I transmembrane glycoprotein. It contains an IgV-like region, an IgC-like region, an amino acid intracellular region, and a transmembrane hydrophobic region. Tumor cells, antigen presenting cells (APCs), activated T cells, activated B cells, monocytes, macrophages, dendritic cells DCs, thymic cortical epithelial cells, and placental trophoblast cells [7].

Relationship between expression of PD-L1 and clinicopathology and prognosis of esophageal cancer
The relationship between PD-L1 expression and clinical pathology and prognosis of esophageal cancer remains controversial. A retrospective study of 378 patients with T2-T4a esophageal squamous cell carcinoma showed that PD-L1 expression in esophageal squamous carcinoma cells was associated with clinical pathological parameters such as age, differentiation, stage, metastasis, and DFS. Multivariate COX analysis did not. It can be shown that PD-L1 is an independent prognostic factor [8]. T Konno-Kumagai, et al. [9] found that high expression of PD-L1 in metastatic lymph nodes of esophageal squamous cell carcinoma was significantly associated with adverse clinical outcomes. However, a study by Chen K, et al.

Key words: esophageal cancer, PD-L1, radiotherapy
Received: March 20, 2019; Accepted: March 27, 2019; Published: March 29, 2019

Volume 4: 1-4
Radiotherapy can cause up-regulation of pd-l1 expression

Radiotherapy is widely used in the treatment of primary and metastatic tumors. The biological response of a tumor to radiation includes DNA damage, regulation of signal transduction, and changes in the tumor microenvironment. Lim, et al. [14] compared the expression of PD-L1 after neoadjuvant chemoradiotherapy with esophageal squamous cell carcinoma and found that radiotherapy and chemotherapy can up-regulate PD-L1 expression. Ronan, et al. [15] also found that radiotherapy can up-regulate PD-L1 expression in a rat model of esophageal adenocarcinoma in a dose-dependent manner. Similar results were observed in other tumors. Radiotherapy increased PD-L1 expression in the head and neck squamous cell carcinoma cell line, and the effect on PD-L1 expression was dose-dependent [16]. High-dose radiotherapy can up-regulate PD-L1 expression [17] in pancreatic ductal adenocarcinoma. The expression of PD-L1 was significantly increased after neoadjuvant chemoradiotherapy for rectal cancer [18].

Overview of pd-l1 up-regulation related signaling pathways

PD-L1 is considered to be an important mediator of epithelial-mesenchymal transition (EMT) in certain human cancer tissues such as lung cancer, colorectal cancer, and head and neck cancer. The expression of PD-L1 in EMT-positive tumor samples was higher than that in EMT-negative tumor samples. PD-L1 promotes EMT and the role of tumor stem cell initiation and maintenance. PD-L1 overexpression enhances mesenchymal markers (N-cadherin, ZEB1 and Vimentin), resulting in EMT phenotype of ECA-109 cells [19]. A study by Alsulimnan, et al. [20] suggested that the induction of epithelial mesenchymal transition in human breast cancer epithelial cells mainly up-regulates the expression of PD-L1 by activating the PI3K/Akt pathway. Another study found that PD-L1 expression induces epithelial mesenchymal transition [21] in renal cell carcinoma by activating the transcription factor SREBP-1.C.A study by Aung K, et al. [22] found that inhibition of GSK-3β induced EMT phenotype and up-regulated PD-L1 expression. EMT-transformed tumor cells have the ability to induce T cell apoptosis.

Studies have shown that epidermal growth factor receptor (EGFR) activation up-regulates PD-L1 levels in lung cancer patients, a finding that links the EGFR pathway to PD-L1 expression [23]. Hoi, et al. [24] found that PD-L1 expression and EGFR and ERK activation were significantly induced in esophageal squamous carcinoma cell lines after standard chemotherapy, confirming that up-regulation of PD-L1 by esophageal squamous cell carcinoma after chemotherapy is via EGFR/ERK signaling pathway. By age Zhang, W, et al. [25] showed that PD-L1 expression was significantly increased in an EGFR-dependent manner by activating EGFR signaling, and that PD-L1 expression decreased dramatically when EGFR signaling was blocked. The study concluded that the up-regulated expression of PD-L1 is not associated with the EGFR-STAT3 signaling pathway, but may be affected by the EGFR–PI3K–AKT, EGFR–Ras–Raf–Erk, and EGR–PLC–γ signaling pathways.

Zhang P, et al. [26] found that PD-L1 and IL-6 were significantly elevated in cisplatin-resistant head and neck squamous carcinoma cells, and anti-IL-6/STAT3 antibodies partially inhibited IL-6 and PD-L1 expression. Shen, et al. [27] indicated that radiotherapy can up-regulate the expression of PD-L1 in tumor cells in a time- and dose-dependent manner. IL-6 signaling enhances the anti-radiation ability of lung cancer cells by promoting DNA repair after irradiation, suggesting that PD-L1 expression may be related to IL-6.

Jin, et al. [28] found that Rb hyperphosphorylation down-regulated the expression of PD-L1 induced by radiotherapy by inhibiting NF-kB activity. Chen, et al. [29] showed that radiotherapy combined with toll-like receptor agonist CPG-ODN7909 can down-regulate PD-L1 expression by inhibiting NF-kB signaling pathway, suggesting that PD-L1 expression may be regulated by NF-kB signaling pathway.

A recent study by Dovedi, et al. [3] has demonstrated that after radiotherapy, the expression of PD-L1 in tumor cells is upregulated by interferon gamma produced by CD8+ T cells. In ALK-derived lung adenocarcinoma, PD-L1 expression [30] can be up-regulated by activating Stat3 and hypoxia-inducible factor-1α (HIF-1α) under normoxia and hypoxia. Low-dose fractionated radiotherapy resulted in up-regulation of tumor cell PD-L1 in a variety of isogened mouse cancer models, and IFN production by CD8+ T cells mediates up-regulation of PD-L1 in tumor cells [3]. Radiotherapy combined with gemcitabine up-regulated the expression of PD-L1 in pancreatic cancer cells [17] by JAK/STAT1 dependent means. Kim, et al. [31] found that radiotherapy up-regulated PD-L1 expression via the PI3K/AKT and STAT3 pathways.

Effect of radiotherapy on pd-1/pd-l1 treatment

Studies have shown that radiotherapy can trigger the recruitment and activation of antigen-presenting cells (APC) and initiate tumor antigen-specific T cell responses by releasing several damage-associated molecular patterns (DAMP) to regulate the host’s immune response to tumor sites. In a mouse model, radiotherapy combined with anti-PD-L1 antibody synergistically enhances anti-tumor immunity by promoting CD8+ T cell infiltration and reducing accumulation of bone marrow-derived suppressor cells (MDSCs) and tumor-infiltrating regulatory T cells (TREGS) [32]. Lim, et al. [33] observed the expression of PD-

L1 and the number of tumor-infiltrating lymphocytes in patients with rectal cancer before and after radiotherapy and chemotherapy. It was found that radiotherapy and chemotherapy can up-regulate PD-L1 expression and increase CD8+ T cell density. Radiotherapy up-regulates the expression of PD-L1 in tumor cells by IFN-γ/STAT3 signaling, which is beneficial to the therapeutic effect of anti-PD-L1. Anti-PD-L1 combined with radiotherapy significantly inhibited tumor growth compared with anti-PD-L1 or radiotherapy alone. Radiotherapy after PD-L1 blockade is associated with decreased CD11b+GR1+ myeloid cell infiltration and enhanced CD45+CD8+ T cell infiltration, while T cell activation markers (including CD69, CD44 and Fasl) are up-regulated, CD8/Treg ratio increase. Radiotherapy activates the immune system, triggering an anti-tumor immune response after cytotoxic death and release of an immune stimulii signal, thereby increasing the transport of T cells to the tumor [17]. Anti-PD-L1 combined with radiotherapy can significantly inhibit tumor growth, including increasing apoptosis, reducing tumor cell proliferation, and restoring CD8+ T cell function. Anti-PD-L1 combined with radiation repairs CD8+ T cell function to expand and restore its effector functions such as cytokine production and cell lysis [31]. Local radiotherapy induces the production of IFN-β, thereby increasing the expression of MHC I in drug-resistant tumor cells and restoring the reactivity of drug-resistant tumors against PD1 treatment. Radiation is sensitive to PD-1 treatment by activating the IFNβ/IFNAR-MHC class I pathway [34]. In addition, in the melanoma, colorectal cancer and triple-negative breast cancer models, radiotherapy combined with PD-1 antibody treatment can improve its anti-tumor efficacy, providing a theoretical basis for the combination therapy strategy.

Summary and outlook

The overall prognosis of esophageal cancer is poor, and finding new treatment measures is a hot topic at home and abroad. The emergence of immunological checkpoint inhibitors has brought us a new dawn. However, immunological checkpoint inhibitors are inefficient and limit their use. In vitro tests initially showed synergistic effects between immunotherapy and radiotherapy. However, the specific mechanisms and the signal pathways involved are complex and require further research. Immunotherapy combined with radiotherapy is expected to bring more gospel to patients with esophageal cancer.

References

7. Ceerar S, Nowak EC, Noelle RJ (2013) B7 family checkpoint regulators in immune regulation and disease. Trends Immunol 34: 556-563. [Crossref]

